# Antihypertensive Selection: Indication, Duration, Adherence

Choose the class from the comorbidity and safety profile, simplify delivery, and reassess the expected BP and laboratory effects after every change.

![Infographic: Antihypertensive Selection: Indication, Duration, Adherence](https://urinenephrology.org/visual-reference/images/antihypertensive-selection.png?v=20261003c)

## Confirm the indication and average

Use reliable BP and review CVD, CKD/UACR, diabetes, HF, pregnancy potential, pulse, and orthostasis. Stage 2 hypertension generally merits two first-line agents from different classes, preferably a suitable single-pill combination. Avoid intensifying an erroneous office-only reading.

## Know the usual first-line choices

A thiazide-type/thiazide-like diuretic, long-acting dihydropyridine calcium-channel blocker, ACE inhibitor, or ARB are common initial classes. Choose an ACE inhibitor or ARB for appropriate albuminuric CKD. A beta blocker is particularly useful with a compelling cardiac indication rather than as a universal first choice.

## Let the adverse-effect pattern guide you

Amlodipine can cause ankle edema; thiazides can lower sodium/potassium; ACE inhibitors can cause cough/angioedema; ACE/ARB/MRA therapy can raise potassium. Match the symptom and chemistry change to the drug before adding a new medicine to counter an avoidable adverse effect.

## Build sustained, obtainable treatment

Prefer a simple daily routine, affordable formulations, and adequate duration of action. A long half-life smooths exposure but also prolongs adverse effects and delays steady state. Do not declare one ARB superior for every outcome from pharmacokinetics alone.

## Attach a monitoring plan

After RAAS initiation/titration, check BP, creatinine, and potassium within 2–4 weeks, sooner when unstable or high risk. Diuretics require sodium/potassium and volume follow-up. Review home readings and symptoms as the dose approaches its full effect.

## When control remains poor

Check adherence, cost, refill gaps, OTC drugs, sodium/volume excess, and home/ABPM confirmation before a resistant-hypertension label. Avoid ACE inhibitor plus ARB. If adverse effects limit therapy, change the responsible component while preserving indicated cardiac/kidney protection.

## Supporting evidence

- [Supporting guideline or source](https://doi.org/10.1161/CIR.0000000000001356)
- [Supporting guideline or source](https://kdigo.org/wp-content/uploads/2026/04/KDIGO-2024-CKD-Guideline.pdf)

## Source lessons

- [medical management updated](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/medical-management-updated.html)
- [medical management](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/medical-management.html)
- [extended half life agents](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/extended-half-life-agents.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.